Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP) Institutional Ownership
CUSIP: 890260839
13F Institutional Holders and Ownership History from Q4 2024 to Q1 2026
Institutions Reporting
70
Shares (Excl. Options)
3,742,749
Price
$15.62
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- TNXP on Nasdaq
- Shares outstanding
- 13,418,426
- Price per share
- $13.75
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 3,742,749
- Total reported value
- $58,486,083
- % of total 13F portfolios
- 0%
- Share change
- +1,384,250
- Value change
- +$19,805,765
- Number of holders
- 70
- Price from insider filings
- $13.75
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- TNXP - Tonix Pharmaceuticals Holding Corp. - Common Stock is tracked under CUSIP 890260839.
- 70 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 70 to 9 between Q4 2025 and Q1 2026.
- Reported value moved from $58,486,083 to $215,880.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 70 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 890260839?
CUSIP 890260839 identifies TNXP - Tonix Pharmaceuticals Holding Corp. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 890260839:
Significant Owners of Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | 9.2% | $19,884,434 | 1,235,058 | Point72 Asset Management, L.P. | 29 Dec 2025 | |||
| BlackRock, Inc. | 6.7% | -14% | $13,348,524 | +$2,726,362 | 854,579 | +26% | BlackRock, Inc. | 31 Dec 2025 |
| VANGUARD GROUP INC | 5% | -22% | $10,521,710 | +$1,822,042 | 673,605 | +21% | The Vanguard Group | 31 Dec 2025 |
As of 31 Dec 2025, 70 institutional investors reported holding 3,742,749 shares of Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP). This represents 28% of the company’s total 13,418,426 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP) together control 27% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6.6% | 884,881 | +30% | 0% | $13,821,842 |
| VANGUARD GROUP INC | 5% | 673,605 | +21% | 0% | $10,521,710 |
| Point72 Asset Management, L.P. | 4.6% | 620,033 | 0.02% | $9,684,915 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 271,904 | +35% | 0% | $4,248,035 |
| STATE STREET CORP | 1.4% | 191,855 | +26% | 0% | $2,996,775 |
| Balyasny Asset Management L.P. | 1.4% | 185,352 | 0.01% | $2,895,199 | |
| NORTHERN TRUST CORP | 1.3% | 174,886 | +3.1% | 0% | $2,731,719 |
| Nuveen, LLC | 0.7% | 93,402 | +508% | 0% | $1,458,939 |
| UBS Group AG | 0.68% | 91,459 | +77% | 0% | $1,428,590 |
| Davidson Kempner Capital Management LP | 0.67% | 90,006 | 0.03% | $1,405,894 | |
| MORGAN STANLEY | 0.31% | 42,038 | +168% | 0% | $656,634 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.25% | 33,404 | +25% | 0% | $521,770 |
| JANE STREET GROUP, LLC | 0.23% | 30,626 | 0% | $478,378 | |
| BANK OF AMERICA CORP /DE/ | 0.23% | 30,314 | +552% | 0% | $473,505 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.22% | 29,662 | +239% | 0% | $463,320 |
| GOLDMAN SACHS GROUP INC | 0.2% | 26,808 | +111% | 0% | $418,741 |
| Bank of New York Mellon Corp | 0.18% | 24,064 | +19% | 0% | $375,876 |
| MILLENNIUM MANAGEMENT LLC | 0.17% | 22,946 | -56% | 0% | $358,417 |
| BARCLAYS PLC | 0.17% | 22,231 | +78% | 0% | $347,249 |
| AQR CAPITAL MANAGEMENT LLC | 0.15% | 20,020 | 0% | $312,713 | |
| Man Group plc | 0.14% | 18,442 | 0% | $288,064 | |
| WELLS FARGO & COMPANY/MN | 0.11% | 15,430 | +115% | 0% | $241,016 |
| Engineers Gate Manager LP | 0.11% | 14,263 | +64% | 0% | $222,788 |
| ALLIANCEBERNSTEIN L.P. | 0.1% | 13,070 | 0% | 0% | $204,153 |
| AMERICAN CENTURY COMPANIES INC | 0.1% | 12,850 | +28% | 0% | $200,717 |
Institutional Holders of Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 15,718 | $215,880 | +$31,533 | $13.75 | 9 |
| 2025 Q4 | 3,742,749 | $58,486,083 | +$19,805,765 | $15.62 | 70 |
| 2025 Q3 | 2,357,754 | $56,965,413 | +$23,004,291 | $24.16 | 60 |
| 2025 Q2 | 1,387,298 | $49,914,163 | +$34,081,287 | $35.98 | 46 |
| 2025 Q1 | 473,835 | $8,469,550 | +$8,375,403 | $17.88 | 24 |
| 2024 Q4 | 5,377 | $1,773 | +$1,773 | $0.33 | 2 |